Your browser doesn't support javascript.
loading
A clinical and economic assessment of adjuvanted trivalent versus standard egg-derived quadrivalent influenza vaccines among older adults in the United States during the 2018-19 and 2019-20 influenza seasons.
Levin, Myron J; Divino, Victoria; Postma, Maarten J; Pelton, Stephen I; Zhou, Zifan; DeKoven, Mitch; Mould-Quevedo, Joaquin.
Affiliation
  • Levin MJ; Departments of Pediatrics and Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA.
  • Divino V; Real World Solutions, IQVIA, Falls Church, VA, USA.
  • Postma MJ; Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Pelton SI; Department of Economics, Econometrics and Finance, Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands.
  • Zhou Z; Centre of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia.
  • DeKoven M; Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA.
  • Mould-Quevedo J; Division of Pediatric Infectious Diseases, Maxwell Finland Laboratory, Boston Medical Center, Boston, MA, USA.
Expert Rev Vaccines ; 23(1): 124-136, 2024.
Article in En | MEDLINE | ID: mdl-38073493
ABSTRACT

BACKGROUND:

Clinical evidence supports use of enhanced influenza vaccines in older adults. Few economic outcome studies have compared adjuvanted trivalent inactivated (aIIV3) and standard egg-derived quadrivalent inactivated influenza vaccines (IIV4e). RESEARCH DESIGN AND

METHODS:

A retrospective cohort study was conducted leveraging deidentified US hospital data linked to claims data during the 2018-19 and 2019-20 influenza seasons. Relative vaccine effectiveness (rVE) was compared in adults aged ≥ 65 years receiving aIIV3 or IIV4e using inverse probability of treatment weighting (IPTW) and Poisson regression. An economic assessment quantified potential real-world cost savings.

RESULTS:

The study included 715,807 aIIV3 and 320,991 IIV4e recipients in the 2018-19 and 844,169 aIIV3 and 306,270 IIV4e recipients in the 2019-20 influenza seasons. aIIV3 was significantly more effective than IIV4e in preventing cardiorespiratory disease (2018-19 rVE = 6.2%; and 2019-20 rVE = 6.0%) and respiratory disease (2018-19 rVE = 8.9%; and 2019-20 rVE = 10.1%). During the 2018-19 influenza season cardiorespiratory hospitalization cost savings for the aIIV3 population were $392 M, and $221 M for the 2019-20 season. Respiratory hospitalization cost savings for the aIIV3 population were $145 M and $97 M, respectively.

CONCLUSIONS:

Our findings suggest that aIIV3 provides clinical and economic advantages versus IIV4e in the elderly.
Flu vaccines do not work as well in older adults due to the aging of their immune system. One approach to improving vaccine efficacy is the addition of a substance, or adjuvant, to the vaccine in order to boost an individual's immune response. This study evaluated an adjuvanted vaccine compared to an unadjuvanted vaccine for preventing cardiorespiratory hospitalizations and hospitalization costs. The findings demonstrated that the adjuvanted flu vaccine, compared to the unadjuvanted vaccine, prevented more hospitalizations and greatly reduced associated hospital costs.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human Limits: Aged / Humans Country/Region as subject: America do norte Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human Limits: Aged / Humans Country/Region as subject: America do norte Language: En Journal: Expert Rev Vaccines Journal subject: ALERGIA E IMUNOLOGIA Year: 2024 Document type: Article Affiliation country: Estados Unidos